Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review

Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review

Abstract Background Bone marrow cancer has been at the forefront of cancer research. The propensity of cancers to extravasate to the bone makes it a very relevant topic in the topology of this heterogeneous disease. Our narrative review article addresses Brentuximab vedotin (BV) resistance in classi...

Full description

Bibliographic Details
Main Authors:	Dayeeta Bera, Dattatreya Roy
Format:	Article
Language:	English
Published:	SpringerOpen 2024-02-01
Series:	Future Journal of Pharmaceutical Sciences
Subjects:	Brentuximab vedotin Drug resistance R/r- classic Hodgkin lymphoma Reed-Sternberg cells Oncotherapy
Online Access:	https://doi.org/10.1186/s43094-024-00590-9

Similar Items

Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01)

Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis
by: Aimee Schad, et al.
Published: (2023-09-01)

Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
by: Kana Nagashima, et al.
Published: (2020-03-01)

Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
by: G. S. Tumyan
Published: (2018-11-01)

A case of metachronous peripheral T‐Cell non‐Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin
by: Federico Meconi, et al.
Published: (2020-08-01)

Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
by: A. J. N. Raymakers, et al.
Published: (2020-10-01)

The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19
by: Rajabto W, et al.
Published: (2022-06-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy
by: Wilbur Montana, et al.
Published: (2017-09-01)

Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report
by: Chunting Zhu, et al.
Published: (2022-01-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure
by: Norihiro Ueda, et al.
Published: (2023-12-01)

The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors
by: Ruizhi Zhao, et al.
Published: (2024-03-01)

Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience
by: N. V. Myakova, et al.
Published: (2016-03-01)

Pharmaceutical assessment of the rationale of the application of chemotherapy schemes containing immunotherapeutic drugs in the treatment of classical Hodgkin's lymphoma
by: M. R. Matushchak, et al.
Published: (2023-06-01)

Case Report: Brentuximab Vedotin Associated Acute Pancreatitis in a Pediatric Hodgkin Lymphoma Patient: Case Report and Literature Review
by: Ewelina Truszkowska, et al.
Published: (2022-08-01)

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma
by: Jennifer E. Agrusa, et al.
Published: (2023-05-01)

Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report
by: Federica Giannotti, et al.
Published: (2024-03-01)

Complete remission of Hodgkin’s lymphoma in a pediatric patient with TTN gene mutation treated with brentuximab vedotin combined chemotherapy without anthracyclines: A case report
by: Ying Li, et al.
Published: (2022-10-01)

Hodgkin Reed–Sternberg-Like Cells in Non-Hodgkin Lymphoma
by: Paola Parente, et al.
Published: (2020-11-01)

Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
by: Takashi Onaka, et al.
Published: (2018-05-01)

Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma
by: Joana Ferra, et al.
Published: (2021-02-01)

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
by: Fulvio Massaro, et al.
Published: (2022-02-01)

Hodgkin lymphoma: current conception and unresolved questions
by: Gurtovoj V.A., et al.
Published: (2010-01-01)

Clinical Observation of 32 Cases of Malignant Lymphoma Treated with Brentuximab Vedotin Combined with Chemotherapy
by: CHAI Xiaofei, et al.
Published: (2023-03-01)

Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT
by: Agnieszka Giza, et al.
Published: (2023-07-01)

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
by: Yujie Zhang, et al.
Published: (2022-07-01)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
by: Timothy J Voorhees, et al.
Published: (2020-10-01)

Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol
by: Masahiro Sekimizu, et al.
Published: (2018-02-01)

Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study
by: Xudong Zhang, et al.
Published: (2023-12-01)

Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine for first-line treatment of stage IV HL: cost impact on subsequent lines in Italy
by: Francesca Fiorentino, et al.
Published: (2023-01-01)

Brentuximab vedotin + AVD in cHL: cost impact on adverse events, toxicity, second malignancies, end-of-life and subsequent lines of therapy in Italy
by: Francesca Fiorentino, et al.
Published: (2023-10-01)

Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches
by: Walter Hanel, et al.
Published: (2022-12-01)

Therapeutic response in patients with CD30+ lymphomas to biological therapy
by: Cakić Jelena, et al.
Published: (2020-01-01)

Modern approaches in relapsed and refractory Hodgkin lymphoma treatment: literature review and own experience
by: Natalia S. Tsaplina, et al.
Published: (2022-11-01)

Synchronous Nodal Involvement of Metastatic Adenocarcinoma and Classical Hodgkin's Lymphoma
by: Ritesh Sachdev, et al.
Published: (2017-08-01)

Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
by: Theodoros P. Vassilakopoulos, et al.
Published: (2019-07-01)

Identification of Reed-Berezovsky-Sternberg cells in lymphatic nodes in classic Hodgkin's lymphoma by flow cytometry: a clinical case series
by: Firuza М. Abbasbeyli, et al.
Published: (2023-06-01)

Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy
by: Roser Velasco, et al.
Published: (2021-12-01)

Molecular Pathogenesis of Hodgkin Lymphoma: Past, Present, Future
by: Marc Bienz, et al.
Published: (2020-09-01)